BioQ Pharma has expanded its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready-to-use BioQ Pharma infusion pharmaceutical in the U.S. BioQ Pharma is responsible for developing and supplying the unit-dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product. “We are pleased to grow our relationship with Sandoz, a leader ...